Show simple item record

Developing a Gaucher Disease Pharmacological Model of the Blood-Brain Barrier

dc.contributor.advisorMuro, Silvia
dc.contributor.advisorSolomon, Melani
dc.contributor.advisorFeldman, Ricardo
dc.contributor.advisorSrikanth, Manasa
dc.contributor.advisorGray, Kevin
dc.contributor.authorSelvadoss, Andrew
dc.date.accessioned2021-05-14T10:06:32Z
dc.date.available2021-05-14T10:06:32Z
dc.date.issued2021-04
dc.identifierhttps://doi.org/10.13016/1dzw-qfud
dc.identifier.urihttp://hdl.handle.net/1903/27053
dc.description.abstractGaucher disease is a genetic disorder that leads to the lysosomal enzyme glucocerebrosidase (GCase) being unable to function correctly. The enzyme breaks down glucocerebroside (GluCer) and in the case of Gaucher disease, a buildup of GluCer leads to various conditions which can often be neuropathic. A common treatment for Gaucher disease and other lysosomal storage diseases is enzyme replacement therapy, which consists of intravenously delivered recombinant enzymes. However, this treatment has an inability to treat the central nervous system (CNS) because of its inability to cross the blood-brain barrier (BBB). In vitro studies with Gaucher afflicted BBB cellular systems are needed to test the delivery of novel recombinant enzymes across the BBB. These experiments however are severely limited by the scarcity and expense of Gaucher endothelial cells, astrocytes, and neurons, which compose the BBB. This project's goal was to develop a pharmacological model of Gaucher disease using cellular systems involving treating healthy endothelial cells, astrocytes, to exhibit the Gaucher phenotype, and iPS service Gaucher neurons. First, cellular systems were treated with conduritol beta-epoxide (CBE), an inhibitor of GCase. Treatment with CBE lowered GCase activity and increased GluCer accumulation in both cell types, and to a similar extent as a genetic model- Gaucher skin fibroblasts. An in vitro model of the Gaucher BBB was created using a transwell system with CBE treated endothelial cells on the apical side, astrocytes on the basal side of the filter and iPS service Gaucher neurons in the basal well. Transport of GCase, modified to transcytose more efficiently was tested on the Gaucher BBB model, where more efficient transcytosis, lysosomal colocalization, and effects were observed when compared to control GCase. This model presents a promising step towards testing potential therapeutics for Gaucher disease.en_US
dc.description.sponsorshipIBBRen_US
dc.subjectGaucher Diseaseen_US
dc.subjectDrug Deliveryen_US
dc.subjectGCaseen_US
dc.subjectLysosomal Storage Diseaseen_US
dc.subjectBlood-Brain Barrieren_US
dc.subjectNeuronsen_US
dc.subjectAstrocytesen_US
dc.subjectEndothelial Cellsen_US
dc.subjectHBMECen_US
dc.subjectFibroblastsen_US
dc.titleDeveloping a Gaucher Disease Pharmacological Model of the Blood-Brain Barrieren_US
dc.typeOtheren_US
dc.relation.isAvailableAtMaryland Center for Undergraduate Research
dc.relation.isAvailableAtDigital Repository at the University of Maryland
dc.relation.isAvailableAtUniversity of Maryland (College Park, Md)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record